Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Annexon Biosciences has raised $86.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Annexon Biosciences's investors include BlackRock, Janus Henderson Investors, New Enterprise Associates, Redmile Group, Blackstone Life Sciences.
Annexon Biosciences is headquartered in South San Francisco, United States.
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Annexon Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Annexon Biosciences — Funding & Investors." VCBacked, November 12, 2025, https://www.vcbacked.co/company/annexon-biosciences. Accessed July 19, 2026.
VCBacked. (2025). Annexon Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/annexon-biosciences
{{cite web |title=Annexon Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/annexon-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated